People: Vertex Pharmaceuticals Inc (VRTX.O)
VRTX.O on Nasdaq
78.40USD
24 May 2013
78.40USD
24 May 2013
Price Change (% chg)
$-0.08 (-0.10%)
$-0.08 (-0.10%)
Prev Close
$78.48
$78.48
Open
$77.50
$77.50
Day's High
$78.46
$78.46
Day's Low
$76.73
$76.73
Volume
859,226
859,226
Avg. Vol
2,507,361
2,507,361
52-wk High
$87.47
$87.47
52-wk Low
$38.44
$38.44
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Jeffrey Leiden |
57 | 2012 | Chairman of the Board, President, Chief Executive Officer |
Ian Smith |
47 | 2008 | Chief Financial Officer, Executive Vice President |
Peter Mueller |
56 | 2009 | Executive Vice President - Global Research and Development, Chief Scientific Officer |
Stuart Arbuckle |
47 | 2012 | Executive Vice President, Chief Commercial Officer |
Kenneth Horton |
46 | 2012 | Executive Vice President, Chief Legal Officer |
Paul Silva |
47 | 2011 | Senior Vice President, Corporate Controller |
Megan Pace |
40 | 2012 | Senior Vice President - Corporate Communications |
Amit Sachdev |
45 | 2013 | Senior Vice President - Global Government Strategy, Market Access and Value |
Christiana Stamoulis |
42 | 2009 | Senior Vice President - Corporate Strategy and Business Development |
Bruce Sachs |
53 | 2011 | Co-Lead Independent Director |
Elaine Ullian |
65 | 2011 | Co-Lead Independent Director |
Joshua Boger |
61 | 2009 | Director |
David Altshuler |
48 | 2012 | Independent Director |
Terrence Kearney |
58 | 2011 | Independent Director |
Yuchun Lee |
47 | 2012 | Independent Director |
Margaret McGlynn |
53 | 2011 | Independent Director |
Wayne Riley |
53 | 2010 | Independent Director |
Michael Partridge |
Vice President - Investor Relations |
Biographies
| Name | Description |
|---|---|
Jeffrey Leiden |
Dr. Jeffrey M. Leiden, M.D., Ph.D., has been appointed as Chairman of the Board, President, Chief Executive Officer of Vertex Pharmaceuticals Inc., effective May 2012. Dr. Leiden is Company's Chief Executive Officer and President, a position he was appointed to on February 1, 2012 after joining the Company as CEO Designee on December 14, 2011. He has been a member of Company's Board of Directors since July 2009 and served as Company's lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden is a senior advisor to Clarus Ventures. Dr. Leiden was a director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012, and was also a member of the Board of Directors of Millennium Pharmaceuticals, Inc., from October 2007 until it was acquired in June 2008. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago. |
Ian Smith |
Mr. Ian F. Smith, CPA, A.C.A., is Chief Financial Officer, Executive Vice President of Vertex Pharmaceuticals Inc., since February 2006. From November 2003 to February 2006, he was Company's Senior Vice President and Chief Financial Officer, and from October 2001 to November 2003, he served as Company's Vice President and Chief Financial Officer. Prior to joining the Company, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst & Young's U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith currently is a member of the Boards of Directors of Acorda Therapeutics, Inc., a drug development company, and Infinity Pharmaceuticals, Inc., a drug development company. Mr. Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales. |
Peter Mueller |
Dr. Peter Mueller, Ph.D., is Executive Vice President - Global Research and Development, Chief Scientific Officer of Vertex Pharmaceuticals Inc. Dr. Mueller is Company's Executive Vice President, Global Research and Development, a position he has held since May 2009, and has been Company's Chief Scientific Officer since July 2003. Dr. Mueller was Company's Executive Vice President, Drug Innovation and Realization, from February 2006 to May 2009, and Company's Senior Vice President, Drug Discovery and Innovation, from July 2003 to February 2006. Prior to joining the Company, Dr. Mueller was the Senior Vice President, Research and Development, of Boehringer Ingelheim Pharmaceuticals, Inc., with responsibility for the development of all drug candidates in the company's portfolio in North America. He led research programs in the areas of immunology, inflammatory cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates and held several positions in basic research, medicinal chemistry and management. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretic Organic Chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University. |
Stuart Arbuckle |
Mr. Stuart A. Arbuckle has been appointed as Executive Vice President, Chief Commercial Officer of Vertex Pharmaceuticals Inc., effective September 04, 2012. Prior to joining the Company, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000 person biotechnology company, from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He currently is a member of the Board of Directors of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer. Mr. Arbuckle holds a BSc in pharmacology and physiology from the University of Leeds. |
Kenneth Horton |
Mr. Kenneth L. Horton has been appointed as Executive Vice President, Chief Legal Officer of Vertex Pharmaceuticals Inc., effective June 08, 2012. Prior to joining the Company, Mr. Horton served as General Counsel and Executive Vice President of Corporate Development at Nordion Inc. (formerly MDS Inc.), a global health science company, from 2005 to 2011. He joined MDS from PerkinElmer, Inc., where he was Vice President, Acquisitions, Ventures and General Counsel for the Life and Analytical Sciences business unit. Mr. Horton began his legal career practicing corporate law at Ropes & Gray in Boston after working as a strategy consultant in the United States and Europe. Mr. Horton currently serves on the Board of Advisors for Beth Israel Deaconess-Needham Hospital and was formerly Chairman of Lumira Capital. Mr. Horton holds an A.B. from Dartmouth College, a J.D. from Harvard Law School and was awarded the D.A.A.D. Direktstipendium for study at the Universitaet Bonn. |
Paul Silva |
Mr. Paul M. Silva is Senior Vice President and Corporate Controller of Vertex Pharmaceuticals Inc., since April 2011. Mr. Silva joined the Companyin August 2007 as Senior Director, Accounting Operations and was Company's Vice President and Corporate Controller from September 2008 through April 2011. Prior to joining the Company, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountain's financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporation from 2002 to April 2005. Mr. Silva holds a B.S. in accounting from Assumption College. |
Megan Pace |
Ms. Megan Pace is the Senior Vice President - Corporate Communications of Vertex Pharmaceuticals Inc., since July 2012. Ms. Pace served as the Vice President, Corporate Communications from May 2010 through July 2012. Prior to joining the Company, Ms. Pace was a Senior Director at Genentech, Inc., a biotechnology company, from 2005 through April 2010, where she led the team responsible for public affairs, product public relations and patient advocacy. Prior to Genentech, she held government affairs and public relations roles at Eli Lilly & Company, and worked at Porter Novelli, a global public relations firm, where she managed disease awareness and public health campaigns for several biopharmaceutical companies and government agencies. Ms. Pace holds a B.A. from the College of Charleston. |
Amit Sachdev |
Mr. Amit K. Sachdev, J.D., is Senior Vice President - Global Government Strategy, Market Access and Value of Vertex Pharmaceuticals Inc., since February 2013. As a Senior Vice President, he has led the government affairs, public policy and patient advocacy functions since he joined the Company in July 2007 and built and managed the Canadian business operations from October 2010 through February 2013. Mr. Sachdev served as Executive Vice President, Health of the Biotechnology Industry Organization (BIO) from April 2005 through June 2007. Mr. Sachdev was the Deputy Commissioner for Policy at the FDA from April 2004 through April 2005, and held several other senior positions within the FDA from September 2002 through April 2004. From 1998 to 2002, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the United States House of Representatives. From 1993 to 1997, Mr. Sachdev practiced law, first at the Chemical Manufacturers Association, and then with the law firm of Ropes & Gray. Mr. Sachdev holds a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law. |
Christiana Stamoulis |
Ms. Christiana Stamoulis, M.B.A., is Senior Vice President - Corporate Strategy and Business Development of Vertex Pharmaceuticals Inc., since October 2010. Prior to joining the Company, she was a Managing Director in Citigroup's Healthcare Banking Group from April 2006 to February 2009. From 2000 to April 2006, Ms. Stamoulis was an investment banker in the Healthcare Investment Banking Group of Goldman, Sachs & Co., where she was a Vice President from January 2002 through April 2006. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis is a member of the Board of Directors of Hologic, Inc., a company focused on diagnostics, medical imaging systems and surgical products for women. Ms. Stamoulis holds a B.S. in Economics and a B.S. in Architecture from the Massachusetts Institute of Technology and an M.B.A. from the MIT Sloan School of Management. |
Bruce Sachs |
Mr. Bruce I. Sachs is Co-Lead Independent Director of Vertex Pharmaceuticals Inc. Mr. Sachs is a General Partner at Charles River Ventures, a venture capital firm he joined in 1999. In 1998 and 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. In 1997 and 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer at Xylogics, Inc. Mr. Sachs was a director of BigBand Networks, Inc., a network-based platform company, from 2005 through June 2009. Mr. Sachs holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University and an M.B.A. from Northeastern University. |
Elaine Ullian |
Ms. Elaine S. Ullian is Co-Lead Independent Director of Vertex Pharmaceuticals Inc. From 1996 through January 2010, she served as President and Chief Executive Officer of Boston Medical Center, a private, not-for-profit, 626-bed, academic medical center with a community-based focus. From 1994 to 1996, she served as President and Chief Executive Officer of Boston University Medical Center Hospital. From 1987 to 1994, Ms. Ullian served as President and Chief Executive Officer of Faulkner Hospital. She also serves as a director of Thermo Fisher Scientific Inc. and Hologic, Inc. In addition, Ms. Ullian was a member of the Board of Directors of Valeant Pharmaceuticals, Inc. from 2005 through 2007. Ms. Ullian holds a B.A. in political science from Tufts University and an M.P.H. from the University of Michigan. |
Joshua Boger |
Dr. Joshua S. Boger, Ph.D., is Director of Vertex Pharmaceuticals Inc. Dr. Boger is the founder of Vertex. He was Chief Executive Officer from 1992 through May 2009. He was Chairman of the Board from 1997 until May 2006 and President from inception until December 2000, and from 2005 through February 2009. He was Chief Scientific Officer from 1989 until May 1992. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. |
David Altshuler |
Dr. David Altshuler, M.D., Ph.D., has been appointed as Independent Director of Vertex Pharmaceuticals Inc., effective May 24, 2012. Dr. Altshuler is the Director of the Program in Medical and Population Genetics at the Broad Institute of Harvard University and the Massachusetts Institute of Technology, a position he has held since 2003. He has served as the Institute's Deputy Director and Chief Academic Officer since 2009. He is one of four founding members of the Broad Institute, a research collaboration of Harvard, MIT, The Whitehead Institute and the Harvard Hospitals. Dr. Altshuler joined the faculty at Harvard Medical School and the Massachusetts General Hospital in 2000 and has held the academic rank of Professor of Genetics and Medicine since 2008. He has served as Adjunct Professor of Biology at MIT since 2012. Dr. Altshuler earned a B.S. from MIT, a Ph.D. from Harvard University and an M.D. from Harvard Medical School. Dr. Altshuler completed his clinical training in Internal Medicine, and in Endocrinology, Diabetes and Metabolism, at the Massachusetts General Hospital. |
Terrence Kearney |
Mr. Terrence C. Kearney is Independent Director of Vertex Pharmaceuticals Inc., since May 17, 2011. Mr. Kearney served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from April 2006 to January 2011. From April 2004 to April 2006, he served as Hospira's Senior Vice President, Finance, and Chief Financial Officer, and he served as Acting Chief Financial Officer through August 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories from 2001 to April 2004. From 1996 to 2001, Mr. Kearney was Divisional Vice President and Controller for Abbott's International Division. He received his B.S. in biology from the University of Illinois and his M.B.A. from the University of Denver. |
Yuchun Lee |
Mr. Yuchun Lee has been appointed as Independent Director of Vertex Pharmaceuticals Inc., since September 14, 2012. Mr. Lee was the Vice President of IBM's Enterprise Marketing Management Group from November 2010 through January 2013. Mr. Lee co-founded Unica Corporation, a provider of software and services used to automate marketing processes, in 1992, and was Unica's President and/or Chief Executive Officer from 1992 through November 2010, when Unica was acquired by IBM. From 1989 to 1992, Mr. Lee was a senior consultant at Digital Equipment Corporation, a supplier of general computing technology and consulting services. Mr. Lee holds B.S. and M.S. degrees in electrical engineering and computer science from the Massachusetts Institute of Technology and an M.B.A. from Babson College. |
Margaret McGlynn |
Ms. Margaret G. McGlynn is Independent Director of Vertex Pharmaceuticals Inc., since May 2011. Ms. McGlynn has served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, since July 2011. Ms. McGlynn served as President, Vaccines and Infectious Diseases of Merck & Co., Inc. from 2005 until 2009. Ms. McGlynn joined Merck in 1983 and served in a variety of marketing, sales and managed care roles. Currently, Ms. McGlynn serves as a member of the Board of Directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, and Amicus Therapeutics, Inc., a biopharmaceutical company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Ms. McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo. |
Wayne Riley |
Dr. Wayne Joseph Riley, M.D., M.B.A., is Independent Director of Vertex Pharmaceuticals Inc., since July 2010. Dr. Riley is President and Chief Executive Officer of Meharry Medical College, a position he has held since January 2007. In addition, he holds the academic rank of Professor of Internal Medicine at both Meharry and Vanderbilt University Schools of Medicine. From May 2004 to December 2006, Dr. Riley served as a corporate officer and member of the executive management team as Vice President and Vice Dean for Health Affairs and Governmental Relations and Associate Professor of Medicine at Baylor College of Medicine, and Assistant Chief of Medicine at Ben Taub General Hospital, Baylor's primary adult public hospital teaching affiliate. He served as Assistant Dean for Education at Baylor College of Medicine from 2000 to 2004. Dr. Riley is a member of the Board of Directors of Pinnacle Financial Partners, Inc., a financial services holding firm, and HCA Holdings, Inc. Dr. Riley earned a B.A. from Yale University, an M.P.H. in health systems management from the Tulane University School of Public Health and Tropical Medicine, an M.D. from the Morehouse School of Medicine and an M.B.A. from the Jones Graduate School of Business, Rice University. |
Michael Partridge |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Jeffrey Leiden |
5,656,680 |
Ian Smith |
3,109,190 |
Peter Mueller |
3,614,890 |
Stuart Arbuckle |
4,808,700 |
Kenneth Horton |
2,802,740 |
Paul Silva |
-- |
Megan Pace |
-- |
Amit Sachdev |
2,503,160 |
Christiana Stamoulis |
-- |
Bruce Sachs |
-- |
Elaine Ullian |
-- |
Joshua Boger |
10,148,400 |
David Altshuler |
-- |
Terrence Kearney |
-- |
Yuchun Lee |
-- |
Margaret McGlynn |
-- |
Wayne Riley |
-- |
Michael Partridge |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Jeffrey Leiden |
0 | 0 |
Ian Smith |
346,133 | 4,903,390 |
Peter Mueller |
419,300 | 8,200,780 |
Stuart Arbuckle |
0 | 0 |
Kenneth Horton |
0 | 0 |
Paul Silva |
0 | 0 |
Megan Pace |
0 | 0 |
Amit Sachdev |
0 | 0 |
Christiana Stamoulis |
0 | 0 |
Bruce Sachs |
0 | 0 |
Elaine Ullian |
0 | 0 |
Joshua Boger |
1,598,785 | 19,527,910 |
David Altshuler |
0 | 0 |
Terrence Kearney |
0 | 0 |
Yuchun Lee |
0 | 0 |
Margaret McGlynn |
0 | 0 |
Wayne Riley |
0 | 0 |
Michael Partridge |
0 | 0 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
